LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,700 | -16.3% | 15,000 | 0.0% | 0.01% | -16.7% |
| Q2 2023 | $21,150 | -6.0% | 15,000 | 0.0% | 0.01% | -14.3% |
| Q1 2023 | $22,500 | +28.2% | 15,000 | 0.0% | 0.01% | +16.7% |
| Q4 2022 | $17,550 | +3.2% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $17,000 | -29.2% | 15,000 | 0.0% | 0.01% | -25.0% |
| Q2 2022 | $24,000 | +4.3% | 15,000 | 0.0% | 0.01% | +33.3% |
| Q1 2022 | $23,000 | -37.8% | 15,000 | 0.0% | 0.01% | -33.3% |
| Q4 2021 | $37,000 | -2.6% | 15,000 | 0.0% | 0.01% | -10.0% |
| Q3 2021 | $38,000 | -11.6% | 15,000 | 0.0% | 0.01% | -16.7% |
| Q2 2021 | $43,000 | +7.5% | 15,000 | 0.0% | 0.01% | +9.1% |
| Q1 2021 | $40,000 | +53.8% | 15,000 | 0.0% | 0.01% | +37.5% |
| Q4 2020 | $26,000 | +85.7% | 15,000 | 0.0% | 0.01% | +60.0% |
| Q3 2020 | $14,000 | +7.7% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $13,000 | +8.3% | 15,000 | 0.0% | 0.01% | -16.7% |
| Q1 2020 | $12,000 | -7.7% | 15,000 | 0.0% | 0.01% | +50.0% |
| Q4 2019 | $13,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
| Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
| Raffles Associates | 93,590 | $236,000 | 0.22% |
| Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
| DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
| Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
| Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
| Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |